|
|
||||||||
Ann Thorac Surg 2007;83:993-1001
© 2007 The Society of Thoracic Surgeons
a Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina
b Cardiothoracic Surgery Associates of North Texas, Dallas, Texas
c University of Cincinnati Surgeons, Inc, Cincinnati, Ohio
d Division of Cardiac Surgery, Brigham and Womens Hospital, Boston, Massachusetts
e Division of Cardiovascular and Thoracic Surgery, Missouri Baptist Medical Center, St. Louis, Missouri
f Corgentech, Inc, San Francisco, California
g Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
h Division of Cardiothoracic Surgery, Brody School of Medicine at Eastern Carolina University, Greenville, North Carolina
Accepted for publication October 16, 2006.
* Address correspondence to Dr Alexander, Duke University Medical Center, DUMC Box 3850, Durham, NC 27710 (Email: john.h.alexander{at}duke.edu).
Background: Secondary prevention medications are beneficial after acute coronary syndromes, but these benefits are less clear after coronary artery bypass graft surgery. We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes.
Methods: Patients undergoing coronary artery bypass graft surgery in the PREVENT IV trial (n = 2970) were surveyed for use of antiplatelet agents, ß-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and lipid-lowering agents after hospital discharge and at 1 year. Patients were categorized based on their percentage use of indicated medications after hospital discharge. Cox modeling was used to determine the association between medication use categories and rates of death or myocardial infarction through 2 years after adjustment for clinical factors, the number of indicated medications, and treatment propensity.
Results: Rates of use of antiplatelet agents and lipid-lowering agents were high at discharge and at 1 year, but use of ß-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was suboptimal. There was a stepwise association between medication use at discharge and patient outcomes (p for trend = 0.014). Patients taking 50% or less of indicated medications at discharge had a significantly higher 2-year rate of death or myocardial infarction (8.0% versus 4.2%; adjusted hazard ratio, 1.69; 95% confidence interval, 1.12 to 2.55; p = 0.013) than those taking all indicated medications.
Conclusions: Greater use of indicated secondary prevention medications after coronary artery bypass graft surgery is associated with a lower 2-year rate of death or myocardial infarction. These data underscore the importance of appropriate secondary prevention measures to improve long-term clinical outcomes after coronary artery bypass graft surgery.
This article has been cited by other articles:
![]() |
R. H. Jones The Year in Cardiovascular Surgery J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1707 - 1718. [Full Text] [PDF] |
||||
![]() |
T. Gershlick and M. Thomas PCI or CABG: which patients and at what cost? Heart, October 1, 2007; 93(10): 1188 - 1190. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |